Overview

HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Status:
RECRUITING
Trial end date:
2028-03-10
Target enrollment:
Participant gender:
Summary
To evaluate HAIC combined with Sintilimab plus bevacizumab biosimilar for advanced hepatocellular carcinoma.
Phase:
PHASE2
Details
Lead Sponsor:
Fudan University
Treatments:
sintilimab